ATE276768T1 - Arzneimittel gegen hepatitis - Google Patents

Arzneimittel gegen hepatitis

Info

Publication number
ATE276768T1
ATE276768T1 AT99909297T AT99909297T ATE276768T1 AT E276768 T1 ATE276768 T1 AT E276768T1 AT 99909297 T AT99909297 T AT 99909297T AT 99909297 T AT99909297 T AT 99909297T AT E276768 T1 ATE276768 T1 AT E276768T1
Authority
AT
Austria
Prior art keywords
hepatitis
poly
drugs
present
dioleoylglycerol
Prior art date
Application number
AT99909297T
Other languages
English (en)
Inventor
Kazuko Hirabayashi
Junzo Seki
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of ATE276768T1 publication Critical patent/ATE276768T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
AT99909297T 1998-03-24 1999-03-23 Arzneimittel gegen hepatitis ATE276768T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7605598 1998-03-24
PCT/JP1999/001438 WO1999048531A1 (fr) 1998-03-24 1999-03-23 Nouveaux remedes contre l'hepatite

Publications (1)

Publication Number Publication Date
ATE276768T1 true ATE276768T1 (de) 2004-10-15

Family

ID=13594103

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99909297T ATE276768T1 (de) 1998-03-24 1999-03-23 Arzneimittel gegen hepatitis

Country Status (12)

Country Link
US (1) US7205282B1 (de)
EP (1) EP1064950B1 (de)
JP (1) JP3804452B2 (de)
KR (1) KR100520738B1 (de)
CN (1) CN1200736C (de)
AT (1) ATE276768T1 (de)
AU (1) AU2855099A (de)
CA (1) CA2325550A1 (de)
DE (1) DE69920418T2 (de)
MY (1) MY134896A (de)
RU (1) RU2226102C2 (de)
WO (1) WO1999048531A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69942581D1 (de) * 1998-05-25 2010-08-26 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer nucleinsäure enthaltenden kompositzusammenstellung
CA2459373A1 (en) * 2001-09-04 2003-03-20 Nippon Shinyaku Co., Ltd. Method of evaluating efficacy of nucleic acid therapy
DE10361502A1 (de) * 2003-12-23 2005-07-28 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Superstruktur-bildende Nukleinsäure-Sequenzen
JP4721642B2 (ja) * 2004-01-20 2011-07-13 サントリーホールディングス株式会社 肝障害を伴う肝臓疾患の予防又は改善剤
EP1886688A4 (de) 2005-05-30 2013-01-09 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer zubereitung eines nukleinsäurehaltigen komplexes
JP5347510B2 (ja) 2007-02-05 2013-11-20 日本新薬株式会社 ポリエチレングリコール誘導体
US20100152433A1 (en) * 2007-03-19 2010-06-17 Michinori Kohara Antiviral agent
CA2727428A1 (en) * 2008-06-19 2009-12-23 Nippon Shinyaku Co., Ltd. Drug carrier
EA019268B1 (ru) * 2010-12-01 2014-02-28 Общество С Ограниченной Ответственностью "Анвилаб" Комбинированное средство, обладающее гепатопротекторным действием
CN105824410B (zh) * 2016-02-22 2017-09-15 维沃移动通信有限公司 一种自动滚屏阅读方法及移动终端
CN110433173A (zh) * 2019-07-19 2019-11-12 成都市海通药业有限公司 聚肌胞注射液及用于降低聚肌胞注射液内毒素的方法
CN116354836A (zh) * 2022-03-25 2023-06-30 深圳市新合生物医疗科技有限公司 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140761A (en) * 1977-04-11 1979-02-20 The United States Of America As Represented By The Department Of Health, Education & Welfare Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5298614A (en) * 1986-01-06 1994-03-29 Nippon Shinyaku Co. Ltd. Size limited double stranded poly I poly(cytidylate/4-thiouridylate)
KR100283601B1 (ko) * 1993-02-19 2001-03-02 아만 히데아키 글리세롤 유도체, 디바이스 및 의약 조성물
TW524693B (en) 1997-10-16 2003-03-21 Nippon Shinyaku Co Ltd Cancer cell nuclease activator

Also Published As

Publication number Publication date
DE69920418D1 (de) 2004-10-28
AU2855099A (en) 1999-10-18
EP1064950A4 (de) 2002-11-27
KR20010042093A (ko) 2001-05-25
WO1999048531A1 (fr) 1999-09-30
CN1294518A (zh) 2001-05-09
EP1064950A1 (de) 2001-01-03
JP3804452B2 (ja) 2006-08-02
DE69920418T2 (de) 2005-10-06
CN1200736C (zh) 2005-05-11
EP1064950B1 (de) 2004-09-22
RU2226102C2 (ru) 2004-03-27
KR100520738B1 (ko) 2005-10-12
CA2325550A1 (en) 1999-09-30
US7205282B1 (en) 2007-04-17
MY134896A (en) 2007-12-31

Similar Documents

Publication Publication Date Title
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
EP1001782A4 (de) 5,6-HETEROARYL-DIPYRIDO (2-3-b:3',2'-f) AZEPINE UND DEREN VERWENDUNG ZUR PROPHYLAXE UND BEHANDLUNG VON HIV-INFEKTIONEN
PL372925A1 (en) Prevention and treatment of restenosis by local administration of drug
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
ATE276768T1 (de) Arzneimittel gegen hepatitis
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
ATE185562T1 (de) Taxol derivate, deren herstellung und diese enthaltende pharmazeutischen zusammenstellungen
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
PL342162A1 (en) Galenic form for oral administration of either immediate or prolonged drug release containing an absorption enhancing agent and application of such absorption enhancing agent
AU7476894A (en) Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
PT1040830E (pt) Medicamento para doencas neurodegenerativas
KR930016102A (ko) 과증식 혈관 질환 치료용 조성물
ATE207743T1 (de) Pharmazeutische präparate zur gezielten behandlung von morbus crohn und colitis ulcerosa
DE69527506D1 (de) Delta 12,16-isotaxol analoge mit antineoplastischer wirkung und pharmazeutische zusammensetzungen sie enthaltend
ATE232100T1 (de) Gegen magensaft geschützte omeprazol- mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen
ITMI922603A1 (it) Composizioni farmaceutiche comprendenti un farmaco, una sostanza polimerica reticolata, un olio ed un agente tensioattivo
ATE324886T1 (de) Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp
IL149134A0 (en) Pharmaceutical compositions containing tofisopam
NZ513650A (en) Pharmaceutical composition for the treatment of urinary incontinence, motion sickness and vertigo
ATE212829T1 (de) Feste, wasserfreie, pharmazeutische zubereitungen für vaginale verwendung
HUP9600455A3 (en) Use of quinoxalines combined with protease-inhibiting compounds for producing pharmaceutical compositions for treating aids and/or hiv infections
DE4494713T1 (de) Arylsulfonamidderivate und diese Derivate enthaltende Arzneimittel
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties